Lecicarbon S Co2-Laxans (Sodium Hydrogen Carbonate, Sodium Dihydrogen Phosphate)

Sodium hydrogen carbonate reacts with sodium dihydrogen phosphate to produce carbon dioxide gas and a mild alkaline environment. The gas creates pressure that softens fecal matter, while the buffering action raises local pH, promoting water retention and facilitating peristalsis for bowel movement.

The appropriate dose of Lecicarbon S Co2-Laxans is determined by the prescribing healthcare professional based on the patient’s condition, age, and response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety in pregnancy or lactation has not been definitively established. Healthcare providers should evaluate the risk‑benefit profile for each individual. If use is considered necessary, it should be under medical supervision and only when the potential benefits outweigh any possible risks.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with osmotic or stimulant laxatives, Lecicarbon S Co2-Laxans uses a buffering and gas‑generating mechanism, which can provide rapid softening of stool with minimal systemic absorption. It is particularly useful for short‑term bowel preparation, whereas other classes may be preferred for chronic constipation management.

Lecicarbon S Co2-Laxans should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the stability of the buffering agents and ensures consistent performance.

The product is administered rectally, typically as an enema. The prescribed amount is inserted into the rectum using the supplied applicator or a suitable device, allowing the formulation to act locally to generate CO₂ and promote bowel evacuation.

Serious risks, though uncommon, include severe abdominal pain, rectal bleeding, allergic reactions such as rash or swelling, and electrolyte disturbances that may arise from excessive fluid loss. Patients should seek immediate medical attention if any of these symptoms occur.

Individuals with known intestinal obstruction, severe inflammatory bowel disease flare‑ups, hypersensitivity to any component of the formulation, or those advised against rectal interventions by their physician should avoid using Lecicarbon S Co2-Laxans.